The drug maker on Saturday announced that its manufacturing facility located at St. Louis, USA has received Form 483 with two observations from the US drug regulator.
In an exchange filing, Alkem Laboratories said, "USFDA had conducted an inspection of the company's manufacturing facility located at St. Louis, USA from 14 June 2021 to 18 June 2021. At the end of the inspection, the company has received Form 483 with two (2) observations."Alkem Laboratories said that it shall submit a detailed response to USFDA within the stipulated timeline to close out all the observations associated with this inspection.
Alkem is a pharmaceutical company with global operations. The company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals, which it markets in India and International markets.
On a consolidated basis, the company reported 27.1% increase in net profit to Rs 240 crore on 7% increase in revenue from operations to Rs 2192.2 crore in Q4 FY21 over Q4 FY20.
Shares of Alkem Laboratories fell 0.95% at Rs 3,137.20 on Friday.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app